Cambridge Cognition AGM to be held on 27 May 2021

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is collaborating with 4YouandMe and The Center for International Emergency Medical Services to investigate the utility of wearables and mobile phones

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced further contract wins in the first half of 2020, taking the order intake to £4.9m for the year to

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has today announced that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials,

Cambridge Cognition Holdings plc (LON:COG), which develops and markets neuroscience technology to assess brain health, announced today its unaudited preliminary results for the year ended 31 December 2019. Highlights 2019 was a year of significant technological and operational advances

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has today announced that the Company has won a contract for three phase II studies with a new pharmaceutical client.  The

Cambridge Cognition Holdings plc (LON:COG, which develops and markets neuroscience technology to assess brain health, is pleased to announce a conditional Placing and Subscription to raise gross proceeds of £1.4 million through the issue of 7,000,000

Cambridge Cognition Holdings PLC (LON:COG), which develops and markets digital solutions to assess brain health, today announced a trading update ahead of the release of the Company’s interim results for the six months to 30 June

Cambridge Cognition Holdings PLC (LON:COG), which delivers digital solutions for optimising cognitive assessment, today announced its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery computerised assessments. This move strengthens the Company’s

Matthew Stork, Chief Executive Officer at Cambridge Cognition said: “We are delighted to have received an order from a leading pharmaceutical company to trial the NeuroVocalix™ platform. We are also very pleased with the results from

Matthew Stork, CEO of Cambridge Cognition said: “We are delighted that Debra has joined the Board. Debra brings with her an immense amount of knowledge and expertise in successful global medical technology businesses and clinical trial